**Supplementary Table S1.** Baseline characteristics of enrolled participants in PPS

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Total (n = 175) | TMF group (n = 89) | Blank control group (n = 86) |
| Age (years), median (Q1, Q3) | 41.0 (33.5, 49.5) | 43.00 (33.0, 53.0) | 40.0 (34.0, 46.8) |
| Age >30 years, n (%) | 151 (86.3) | 76 (85.4) | 75 (87.2) |
| Gender, male, n (%) | 74 (42.3) | 41 (46.1) | 33 (38.4) |
| Positive HBeAg, n (%) [n=188] | 45 (26.5) | 23 (26.1) | 22 (26.8) |
| HBsAg (log10 IU/mL) |  |  |  |
| Overall patients, median (Q1, Q3) [n=188] | 3.27 (2.51, 4.08) | 3.30 (2.57, 4.36) | 3.24 (2.35, 3.92) |
| HBeAg positive patients, median (IQR) [n=48] | 4.71 (4.43, 4.86) | 4.76 (4.70, 4.86) | 4.53 (3.92, 4.85) |
| HBeAg negative patients, median (IQR) [n=140] | 2.94 (2.26, 3.47) | 2.86 (2.36, 3.54) | 2.98 (2.23, 3.44) |
| Serum HBV-DNA (log10 IU/mL) |  |  |  |
| Overall patients, median (Q1, Q3) | 3.69 (3.07, 5.84) | 3.69 (3.13, 6.42) | 3.64 (3.04, 5.63) |
| HBeAg positive patients, median (IQR) [n=48] | 8.34 (8.03, 8.58) | 8.41 (8.28, 8.59) | 8.29 (7.79, 8.50) |
| HBeAg negative patients, median (IQR) [n=140] | 3.36 (2.84, 3.76) | 3.37 (2.88, 4.08) | 3.33 (2.79, 3.75) |
| Serum HBV-DNA >8 log10 IU/mL, n (%) | 35 (20.0) | 21 (23.6) | 14 (16.3) |
| ALT (IU/L) |  |  |  |
| Overall patients, median (Q1, Q3) [n=192] | 21.65 (17.00, 31.00) | 22.00 (18.00, 32.02) | 20.00 (16.00, 29.00) |
| HBeAg positive patients, median (IQR) [n=48] | 25.00 (16.00, 33.00) | 26.00 (18.50, 33.00) | 22.50 (15.25, 31.50) |
| HBeAg negative patients, median (IQR) [n=139] | 21.00 (17.00, 30.00) | 22.00 (18.00, 31.02) | 20.00 (16.00, 25.25) |
| GFR (mL/min), median (Q1, Q3) [n=191] | 98.50 (85.90, 117.30) | 97.40 (85.10, 116.00) | 99.60 (88.40, 118.10) |
| GFR <90 mL/min, n (%) [n=191] | 56 (32.4) | 32 (36.0) | 24 (28.6) |
| Creatinine (µmol/L), median (Q1, Q3) [n=192] | 65.00 (55.78, 79.75) | 66.00 (57.00, 79.00) | 63.00 (53.00, 81.00) |
| Liver stiffness measurement (kPa), median (Q1, Q3) [n=192] | 5.30 (4.53, 6.47) | 5.35 (4.57, 6.62) | 5.30 (4.58, 6.38) |
| FIB4, median (Q1, Q3) [n=191] | 0.99 (0.68, 1.21) | 0.99 (0.69, 1.31) | 0.97 (0.66, 1.18) |
| β-CTx (ng/mL), median (Q1, Q3) [n=69] | 0.41 (0.28, 0.61) | 0.42 (0.29, 0.73) | 0.40 (0.29, 0.55) |
| P1NP (ng/mL), median (Q1, Q3) [n=24] | 46.42 (39.03, 63.58) | 46.42 (38.37, 68.25) | 45.62 (40.85, 61.58) |
| History of hepatitis B treatment, n (%) | 0 | 0 | 0 |
| Hypertension, n (%) | 11 (6.3) | 9 (10.1) | 2 (2.3) |
| Diabetes, n (%) | 4 (2.3) | 4 (4.5) | 0 |
| Cardiovascular and cerebrovascular diseases, n (%) | 0 | 0 | 0 |
| Dyslipidemia, n (%) | 5 (2.9) | 3 (3.4) | 2 (2.3) |
| Fatty liver, n (%) | 6 (3.4) | 3 (3.5) | 3 (3.4) |

PPS: per-protocol set; TMF: tenofovir amibufenamide; Q: quartile; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e-antigen; IQR: interquartile range; HBV-DNA: hepatitis B virus DNA; ALT: alanine aminotransferase; GFR: glomerular filtration rate; β-CTx: β-isomerized C-terminal telopeptides; P1NP: procollagen type I intact N-terminal propeptide.